UiPath Stock Slumps Following Disappointing Outlook For 2022

Shares in automation software developer UiPath (NYSE: PATH) sank by 7.5% yesterday and are trading down a further 14% pre-market following its fourth-quarter earnings call. As has become typical this earnings season, positive results were vastly overshadowed by a less than stellar outlook for the coming year.

How did UiPath’s earnings call go?

Adjusted earnings per share of $0.05 beat analyst expectations of $0.03, and revenue of $289.7 million also outpaced the analysts’ mark of $283 million. These figures provided a mixed bag despite beating predictions, with revenue growing by 39% year-over-year (YoY), but earnings shrinking by over 44% for the same period.

UiPath’s future outlook is what proved to be its undoing, however. The company is expecting revenue of between $1.08 billion and $1.09 billion for the year, while analysts were expecting $1.26 billion. 

What does this mean for UiPath investors?

Reading into such a significant share-price drop immediately after an earnings call can be difficult. Particularly this year, investors have been extremely reactionary to any form of weaker-than-expected outlook. Many companies have suffered similar sell-offs in the 24 hours directly after an earnings call, only for the losses to be at least partially recouped over the following week.

Instead of overreacting to a poor outlook, it pays to assess the company’s fundamentals instead. In UiPath’s case, however, there are some worrying aspects to be assessed. A fourth-quarter loss of $63.1 million, especially compared to net income of $26.3 million in the year-ago period, is certainly cause for concern.

But, importantly, the firm has also made significant strides in increasing its annualized renewal run rate (ARR) — a metric often used to assess how much subscription-based revenue software-as-a-service companies are making. ARR increased by 59% YoY in the fourth quarter, and is forecasted to outpace analyst estimates for the coming year. According to Chief Business Officer Chris Weber, 

“The UiPath team delivered a strong finish to fiscal year 2022 with fourth quarter net new ARR reaching a record $107 million, an increase of 72 percent year-over-year. We believe this is a testament to our highly differentiated end-to-end platform”

Despite some notable concerns, UiPath still has plenty of attractive underlying metrics for investors. The next number of weeks could be particularly telling. Should the stock begin to recover quickly, shareholders can take solace in attributing the decline to a knee-jerk reaction. However, if the slide continues, investors may need to examine the figures further to determine the firm’s true value going forward. It’s certainly a company I plan to keep my eye on over the coming quarter.

Market AnalysisUiPath
Pádraig BolgerPádraig Bolger
  • Pádraig Bolger
  • Financial Writer at MyWallSt

  • Pádraig’s favorite stock is Nike. Growing up as a sports fanatic, seeing Nike collaborate with athletes like Jordan, Lebron, and Ronaldo inspired him and cemented the brand in his mind. Now, despite having failed miserably in his attempts to earn a fabled Nike sponsorship, he still believes in the innovation and creativity behind Nike and is convinced they will only grow stronger as the world’s leading sports brand.

Read More

Smart cities are part of the futureSmart cities are part of the future

What Did ARK Invest Buy This Week? 04/23

Cathie Wood and co. were quick to snap up an exciting new company as it went public, as well as a beaten-down SPAC. Here’s what ARK Invest bought this week.

Market Analysis
Michael O'MahonyMichael O'Mahony
  • Michael O’Mahony
  • Apr 23, 2021


UiPath – The Latest Blockbuster IPO

Jumping 23% in its market debut yesterday, UiPath has had one of the largest software IPOs ever! What do investors need to know?

Market Analysis
James DunneJames Dunne
  • James Dunne
  • Apr 22, 2021

Why has Twitter underperformed the market?Why has Twitter underperformed the market?

What Is Going On Between Elon Musk and Twitter?

Now that Twitter looks to accept a buyout offer from Elon Musk, despite using a “poison pill,” what could happen next?

Expert Opinion
Rory CarronRory Carron
  • Rory Carron
  • Apr 25, 2022

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button